Business Description
Macrogenics Inc
NAICS : 325412
SIC : 2834
ISIN : US5560991094
Total Employee Number:
293Description
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.22 | |||||
Equity-to-Asset | 0.1 | |||||
Debt-to-Equity | 1.72 | |||||
Debt-to-EBITDA | -0.72 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -7.02 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1 | |||||
3-Year EBITDA Growth Rate | 18.7 | |||||
3-Year EPS without NRI Growth Rate | 15.4 | |||||
3-Year FCF Growth Rate | 3.8 | |||||
3-Year Book Growth Rate | -27.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.3 | |||||
9-Day RSI | 42.01 | |||||
14-Day RSI | 48.29 | |||||
3-1 Month Momentum % | 7.5 | |||||
6-1 Month Momentum % | 111.48 | |||||
12-1 Month Momentum % | 144.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.9 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 1.61 | |||||
Days Inventory | 81.58 | |||||
Days Sales Outstanding | 53.96 | |||||
Days Payable | 47.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | -0.38 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.45 | |||||
Operating Margin % | -40.53 | |||||
Net Margin % | -44.79 | |||||
EBITDA Margin % | -32.24 | |||||
FCF Margin % | -45.64 | |||||
OCF Margin % | -44.54 | |||||
ROE % | -130.52 | |||||
ROA % | -28.94 | |||||
ROIC % | -84.34 | |||||
3-Year ROIIC % | -125.5 | |||||
ROC (Joel Greenblatt) % | -123.77 | |||||
ROCE % | -30.79 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.71 | |||||
PB Ratio | 13.12 | |||||
Price-to-Tangible-Book | 13.12 | |||||
EV-to-EBIT | -2.73 | |||||
EV-to-EBITDA | -3.11 | |||||
EV-to-Revenue | 1 | |||||
EV-to-Forward-Revenue | 1.73 | |||||
EV-to-FCF | -2.2 | |||||
Price-to-GF-Value | 1.07 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
Earnings Yield (Greenblatt) % | -36.63 | |||||
FCF Yield % | -26.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MGNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Macrogenics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 157.082 | ||
| EPS (TTM) ($) | -1.1 | ||
| Beta | 0.64 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 56.14 | ||
| 14-Day RSI | 48.29 | ||
| 14-Day ATR ($) | 0.326332 | ||
| 20-Day SMA ($) | 4.464 | ||
| 12-1 Month Momentum % | 144.94 | ||
| 52-Week Range ($) | 1.29 - 5.08 | ||
| Shares Outstanding (Mil) | 63.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Macrogenics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Macrogenics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| Guidance call for 2026 | 2026-05-20 10:30 | 4.52 (+2.96%) | ||
| General meeting for 2026 | 2026-05-19 09:00 | 4.35 (+4.19%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 3.52 (+2.03%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12 10:00 | 3.34 (-2.34%) | ||
| Guidance call for 2026 | 2026-03-11 10:45 | 3.43 (+41.74%) | ||
| Guidance call for 2026 | 2026-03-10 13:40 | 2.36 (+4.89%) | ||
| Annual report for 2025 | 2026-03-09 | 2.23 (+5.69%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 2.23 (+5.69%) |
Show
Entries
Macrogenics Inc Frequently Asked Questions
What is Macrogenics Inc(MGNX)'s stock price today?
The current price of MGNX is $4.33. The 52 week high of MGNX is $5.08 and 52 week low is $1.29.
When is next earnings date of Macrogenics Inc(MGNX)?
The next earnings date of Macrogenics Inc(MGNX) is 2026-08-14 Est..
Does Macrogenics Inc(MGNX) pay dividends? If so, how much?
Macrogenics Inc(MGNX) does not pay dividend.
Guru Commentaries on NAS:MGNX
No articles.
Press Release
Articles on Macrogenics Inc
Headlines
See More- 1
Jun 22, 2026
MacroGenics gains $24.5M payment from Sanofi for Tzield approval
Seeking Alpha • 4:13pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers